Mark G. Malkin, MD, FRCPC
Professor of Neurology
Specialty: Adult Neurology
- Metastases to the Nervous System
- Nervous System Complications of Cancer Therapy
- Neurologic Paraneoplastic Syndromes
- Brain Tumors
- Premedical Studies, University College, Faculty of Arts and Science, University of Toronto, 1973- 1975
- Doctor of Medicine, University of Toronto, Ontario, Canada, 1975-1979
- Straight Intern in Medicine, Sunnybrook Medical Centre, Toronto, Ontario, 1979–1980
- Resident in Medicine, Sunnybrook Medical Centre, Toronto, Ontario, 1980–1981
- Resident in Neurology, University of Toronto Neurology Training Program, Toronto, Ontario, 1981–1984
- Fellow in Neuro-oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, 1985–1988
- Clinical Fellow in Neurology, The New York Hospital, New York, NY, 1986–1988
- Fellow in Neurology, Cornell University Medical College
New York, NY, 1986-1988
- American Academy of Neurology
- American Society of Clinical Oncology
- Canadian Neurological Society
- Society for Neuro-oncology
Central Society for Neurological Research
- 1985 – 1986 Canadian-American Bumper-Borden Foundation Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY
- 1990 – 1993 Clinical Oncology Career Development Award, American Cancer Society
- 2005 Elected to Fellowship, American Academy of Neurology
- 2005 Excellence in Clinical Teaching Award, Department of Neurology, Medical College of Wisconsin
Brief Clinical/Research Interest Statement:
I am a Neuro-oncologist, board certified in Neurology, with expertise in cancer as it affects the nervous system. I care for adult patients with primary brain tumors, metastases to the nervous system, nervous system complications of cancer therapy, and with neurologic paraneoplastic syndromes. My research interests include clinical trials for brain tumor patients, the epidemiology of primary brain tumors, and quality of life studies in brain tumor patients.
Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames M, Tong WPY, Lim S, Figg WD. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. Mayo Clin Proc 1999;74(2):137-145.
Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 2000;46(3):249-259.
Muscat JE, Malkin MG, Thompson S, Shore RE, Stellman SD, McRee D, Neugut A, Wynder EL. Handheld cellular telephone use and risk of brain cancer. JAMA 2000;284(23):3001-3007.
Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros D, Malkin MG. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53(3):259-265.
Khan RB, Raizer JR, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. J Neurooncol 2002;4(1):39-43.
Muscat JE, Malkin MG, Shore RE, Thompson S, Neugut AI, Stellman SD, Bruce J. Handheld cellular telephones and risk of acoustic neuroma. Neurology 2002;58(8):1304-1306.
Selker RG, Shapiro W, Burger P, Blackwood MS, Deutsch M, Arena V, Van Gilder JC, Wu J, Malkin MG, Mealey J Jr, Neal J, Olson J, Robertson JT, Barnett G, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S. The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy and BCNU v. surgery, interstitial radiotherapy boost, external radiotherapy and BCNU. Neurosurgery 2002;51(2):343-355.
Raizer JJ, Malkin MG, Kleber M, Abrey LE. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. J Neurooncol 2004;6(3):247-252.
Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101(4):810-816.
Begemann M, Tsiouris AJ, Malkin MG. Leptomeningeal and ependymal invasion by glioblastoma multiforme. Neurology 2004;63(3):E8.